Recent News

• 04.15.2025 - Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
• 04.15.2025 - Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
• 04.07.2025 - 24th Annual Needham Virtual Healthcare Conference
• 04.07.2025 - 24th Annual Needham Virtual Healthcare Conference
• 04.01.2025 - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 04.01.2025 - Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
• 03.26.2025 - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
• 03.26.2025 - Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
• 03.21.2025 - Definitive Preclinical Toxicokinetic and Toxicology Data Enables Advancement to Clinical Trials for a Potentially Curative Gene Editing Treatment for Chronic Hepatitis B

Recent Filings

• 04.04.2025 - PRE 14A Other preliminary proxy statements
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.26.2025 - 8-K Current report
• 03.26.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities